Pesquisar
Inovio Pharmaceuticals Inc
INOAdicionar à lista de desejos
1.220USD
+0.030+2.52%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
84.18MValor de mercado
PerdaP/L TTM
Mais detalhes de Inovio Pharmaceuticals Inc Empresa
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Informações de Inovio Pharmaceuticals Inc
Código da empresaINO
Nome da EmpresaInovio Pharmaceuticals Inc
Data de listagemDec 08, 1998
CEOShea (Jacqueline Elizabeth)
Número de funcionários134
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 08
Endereço660 W. Germantown Pike
CidadePLYMOUTH MEETING
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19462
Telefone18584103134
Sitehttps://www.inovio.com/
Código da empresaINO
Data de listagemDec 08, 1998
CEOShea (Jacqueline Elizabeth)
Executivos da empresa Inovio Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
111.02K
+23.43%
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
87.59K
--
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.82K
+14.79%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
43.23K
+14.37%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
--
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
111.02K
+23.43%
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
87.59K
--
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.82K
+14.79%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
43.23K
+14.37%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Inovio Pharmaceuticals Inc?
Os cinco principais acionistas de Inovio Pharmaceuticals Inc são: Dr. Jacqueline Elizabeth Shea, Ph.D.
Quantas instituições possuem ações da Inovio Pharmaceuticals Inc (INO)?
Em 2026Q1, 266 instituições possuíam ações da Inovio Pharmaceuticals Inc, com valor de mercado aproximado de 32.85M, representando 40.31% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 3035014.00.